Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04396899RecruitingPhase 1/Phase 2
Stem cell heart patch for advanced heart failure
This early-phase study tests a lab-made heart tissue (“engineered myocardium”) placed surgically to help the heart work better in people with advanced heart failure. It mainly checks safety first, and also looks for signs the patch can improve heart function in selected patients.
Göttingen, Lower SaxonyAges 18–80 - NCT04405583Recruiting
Follow-up study for a heart device in heart failure patients
This study follows people with chronic heart failure to see how well an implanted device (called the Occlutech AFR) works and whether it is safe over time. It may help doctors better understand who benefits and how to manage treatment safely.
BesançonAges 18 years+ - NCT04427241RecruitingPhase 4
Testing Cerebrolysin for prolonged brain injury after bleeding stroke
This study tests whether Cerebrolysin can improve recovery in people who remain in a vegetative or minimally conscious state more than 4 weeks after a bleeding stroke. It also tracks safety, to make sure the treatment is not causing harmful side effects.
SeoulAges 19–120 - NCT04435990RecruitingPhase 3
Allergy shots for dust mites in teens and adults
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
Santiago de Compostela, A CoruñaAges 12–65 - NCT04443010RecruitingPhase 1/Phase 2
Testing a new protein drug with standard treatment for new glioblastoma
This Phase 1/2 study tests whether adding a drug called L19TNF to standard chemoradiotherapy is safe and may work better than standard treatment alone for newly diagnosed glioblastoma. If you qualify, you would be closely monitored for side effects and treatment response.
ZurichAges 18 years+ - NCT04467671RecruitingPhase 2
Tested new blood vessel graft for a heart surgery
This trial studies whether a newer “tissue-engineered” blood vessel graft is safe and works well in children who need a specific heart surgery connection outside the heart. It may help by offering a new type of graft, but your team will screen for size and medical factors first.
Columbus, OhioAges Any age - NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT04481763RecruitingPhase 1/Phase 2
Camrelizumab plus radiation for early triple-negative breast cancer
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
Nanchang, JiangxiAges 18–75 - NCT04496609Recruiting
Testing a spinal stimulation treatment for incomplete spinal cord injury
This trial studies whether a spinal cord stimulation approach plus rehab can improve function and safety in people with an incomplete spinal cord injury who cannot walk. It may help people by supporting rehabilitation over time, but it requires surgery and specific health and imaging conditions.
GarchesAges 18–65 - NCT04547166RecruitingPhase 2/Phase 3
New targeted immune drug plus bevacizumab and chemo for colon cancer
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
Guangzhou, GuangdongAges 18–75 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT04594018RecruitingPhase 3
Test a hair lotion for male pattern hair loss
This Phase 3 study tests whether a specific hair lotion works and is safe for men with male pattern hair loss. It also checks that results are consistent while you keep similar hair care and avoid certain other hair-loss treatments.
Osasco, São PauloAges 18–60 - NCT04602754RecruitingPhase 3
Oral treatment test for type 2 diabetes and bad cholesterol
This Phase 3 study tests whether Berlim 25/20 can improve blood sugar control and cholesterol (LDL) in adults with type 2 diabetes who haven’t met targets despite prior lifestyle guidance and treatment. It also looks at safety, including effects on the heart and medication-related side effects.
Campinas, São PauloAges 18–85 - NCT04623099RecruitingPhase 4
Personalized escitalopram dosing for anxious teens
This study tests whether a genetics-guided approach to choosing and adjusting escitalopram (an anxiety medicine) can improve safety and effectiveness for anxious teens. It also checks that participants have certain anxiety severity scores and can safely take the study medication.
Cincinnati, OhioAges 12–17 - NCT04627701Recruiting
Omega System for symptom relief in enlarged prostate
This trial tests whether the Omega System is safe and effective for improving symptoms from an enlarged prostate (BPH). It looks for men with bothersome urine symptoms and certain prostate size/flow measurements, while carefully excluding prostate cancer and other conditions that could interfere or be unsafe.
BeershebaAges 50 years+ - NCT04629144RecruitingPhase 2
Belimumab for active cryoglobulinemia vasculitis after rituximab
This Phase 2 study tests belimumab (or a placebo) to see if it improves safety and disease control in adults with active cryoglobulinemia vasculitis. You may be eligible if you have had rituximab induction treatment shortly before joining, and your illness is still active.
BloisAges 18 years+ - NCT04656184RecruitingPhase 3
Anakinra vs IVIG for kids who don’t respond to first IVIG
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
Le Kremlin-Bicêtre, Val De MarneAges 3 months–17 years - NCT04666714RecruitingPhase 3
Tested a new medicine to reduce diabetic nerve pain
This Phase 3 study tests Praga formulation to see if it safely reduces nerve pain caused by diabetes. You may qualify if you’re an adult with painful diabetic neuropathy and have certain symptom and pain scores on questionnaires.
Campinas, São PauloAges 18 years+ - NCT04670666RecruitingPhase 3
Study of Madalena for type 2 diabetes not controlled
This Phase 3 study tests Madalena to improve blood sugar control in adults with type 2 diabetes that hasn’t met targets despite diet, exercise, and diabetes medicines. You may join if your recent blood sugar tests and body size fall within specific ranges and you don’t have key medical exclusions.
Hortolândia, São PauloAges 18 years+ - NCT04681534Recruiting
Testing safer adaptive deep brain stimulation for Parkinson’s
This trial studies an “adaptive” form of deep brain stimulation (DBS) that adjusts based on brain signals, and is mainly done when the DBS battery (IPG) needs replacement or when people are getting DBS for the first time. It aims to improve safety and effectiveness for Parkinson’s symptoms by using recorded brain activity during treatment.
MilanAges Any age - NCT04689152RecruitingPhase 3
Cell treatment via liver artery catheter for alcoholic cirrhosis
This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.
Bucheon-siAges 20–71 - NCT04699305Recruiting
Test of ActiGraft for draining skin wounds
This trial studies whether ActiGraft helps heal draining (exuding) skin wounds safely and effectively. If you join, the researchers may use your wound photos and health data to analyze results and publish findings.
Las Vegas, NevadaAges 18 years+ - NCT04734106RecruitingEarly Phase 1
Aloe vera for bladder pain and frequent urination
This early-stage study tests whether aloe vera can reduce symptoms of interstitial cystitis, such as bladder pain and frequent urination. You’d help researchers check both safety and symptom relief.
Winston-Salem, North CarolinaAges 18–80 - NCT04745221Recruiting
Fecal microbes therapy to help prevent graft-versus-host disease
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
Suzhou, JiangsuAges 18–60
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.